Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (2302)	6/8/1999 6:02:00 PM
From: Walter Morton	Read Replies (2) \| Respond to of 2742

Rudy, you don't seem to give much value to the other parts of CIST: Strong Cash Position $9 Million on hand Will receive $3 Million from Immunex in Novmeber 1999 Will receive $1 Million from Immunex in November 2000 Low Debt No preferred shareholders Long-term debt only $260,000 Short-term liabilities only $1.2 Million Promising Research Collaboration Pasteur Merieux Serums & Vaccins, S.A. (PMS&V), the world's largest vaccine company PMS&V to fund vaccine development program over the three-year period for $900,000 $31 Million to Cistron in milestone payments based upon development progress Cistron would receive royalties should PMS&V sell vaccines using Cistron technology Monoclonal Antibody/ IL-1ß Patents So promising that the largest vaccine manufacturer in the world owns Cistron stock So valuable that Immunex agreed to pay $21 Million to avoid a $125 Million lawsuit So promising that that largest vaccine company in the world agreed to pay $31 Million PAI-2 DNA Patent Cistron granted an exclusive sublicense to Biotech Australia Pty. Limited to make, use and sell PAI-2 bioaust.com.au Royalty Agreements TECHNE Corporation (Nasdaq: TECH) rndsystems.com Cistron would receive royalties should PMS&V sell vaccines using Cistron technology Science/Therapeutic Potential Message 9894857 I don't believe CIST is going to sell for >$10, but I would be disappointed with just $1.

To: Rudy Saucillo who wrote (2302)	6/10/1999 8:28:00 PM
From: Walter Morton	Read Replies (1) \| Respond to of 2742

I just stumble upon a company that I had never heard of before today. When I looked at its current and past performance it reminded me of CIST , but it's stock price is much different. Take a look: biz.yahoo.com biz.yahoo.com I know I am not comparing apples to apples, but it's not like comparing apples to oranges. What is the major reason for VICL's stock price to be so much more higher than CIST's compared to book value and sales? I think this will be a good discussion even if you disagree. Two differences that I noticed is that 57 institutions invest in VICL and at least four analyst rate it.